| 前收市價 | 1.3000 |
| 開市 | 1.0000 |
| 買盤 | 0.0000 |
| 賣出價 | 2.9000 |
| 拍板 | 20.00 |
| 到期日 | 2024-05-17 |
| 今日波幅 | 0.8000 - 1.0000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 635 |
Motley FoolBillionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
These stocks are both experts in their respective fields.
InvestorPlaceJust Say No to Drugs: 3 Pharma Stocks to Avoid
From its stellar performance in 2021 to deflating in 2022, the biotech sector continued its stagnation into 2023, highlighting some pharma stocks to avoid. Year-to-date, the S&P Biotechnology Select Industry Index has dropped by 4%. Likewise, the number of biotech firms shrunk by 3% in 2023. Although overlapping with the biotech sector, pharma stocks have started to recover, largely due to new obesity drugs. For example, year-to-date, the VanEck Pharmaceutical ETF (NASDAQ:PPH) has returned 7.69%
ZacksExelixis (EXEL) International Revenue Performance Explored
Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
